June 5, 2018 07:04 AM EDT

With $1.2B NASH deal behind them, Nimbus raises $65M for I/O, other R&D

Brittany Meiling

You might remember Nimbus for the massive NASH deal it inked with Gilead a couple years back — earning a remarkable $400 million upfront. The company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $1.2B NASH deal behind them, Nimbus raises $65M for I/O, other R&D

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?

With $1.2B NASH deal be­hind them, Nim­bus rais­es $65M for I/O, oth­er R&D

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

With $1.2B NASH deal behind them, Nimbus raises $65M for I/O, other R&D

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?